The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV.
A. Leitner
No relevant relationships to disclose
S. Saussele
No relevant relationships to disclose
C. Haferlach
Employment or Leadership Position - Munich Leukemia Laboratory
Stock Ownership - Munich Leukemia Laboratory
G. Goehring
No relevant relationships to disclose
B. Schlegelberger
No relevant relationships to disclose
S. Jung-Munkwitz
No relevant relationships to disclose
U. Proetel
No relevant relationships to disclose
M. Lauseker
No relevant relationships to disclose
M. Pfirrmann
No relevant relationships to disclose
J. Hasford
No relevant relationships to disclose
A. Hochhaus
Research Funding - Bristol-Myers Squibb; Novartis
R. Hehlmann
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Novartis